OncLive |
ASH 2013 Preview: CAR Modified T Cells, Novel Assays, and Ibrutinib
OncLive In this phase I study being presented by Anas Younes, MD, from MSKCC, the combination of first-line ibrutinib and rituximab (R)-CHOP was explored in treatment-naive patients with CD20-positive B-cell non-Hodgkin’s lymphoma (abstract 852). According to … |
Boston Scientific Receives FDA Approval For Promus Premier Everolimus … – HispanicBusiness.com
Boston Scientific Receives FDA Approval For Promus Premier Everolimus …HispanicBusiness.comBy a News Reporter-Staff News Editor at Biotech Business Week — Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporati…
Recent Findings from Institute for Microbiology Has Provided New Information … – HispanicBusiness.com
Recent Findings from Institute for Microbiology Has Provided New Information …HispanicBusiness.comFor more information on this research see: Peripheral blood transcriptome sequencing reveals rejection-relevant genes in long-term heart transplantation…
Analyst: Don't underestimate AbbVie – Medical Marketing and Media
Medical Marketing and Media |
Analyst: Don’t underestimate AbbVie
Medical Marketing and Media Rubin pointed out that the MS drug daclizumab, which is being developed with Biogen Idec, has safety and tolerability issues that undercut its efficacy profile. Rubin said heat surrounding new oral agents “with less safety concerns,” limit the … |
Findings from City University of Hong Kong Update Knowledge of Lymphoma – HispanicBusiness.com
Findings from City University of Hong Kong Update Knowledge of LymphomaHispanicBusiness.comNext, under the guidance of ROR1 fluorescence, the rituximab-conjugated AFM tips were moved to cancer cells to image the cellular morphologies and detect the CD2…
Three Baptist Health hospitals awarded by Washington for organ donation efforts – KyForward.com
Three Baptist Health hospitals awarded by Washington for organ donation effortsKyForward.comBaptist Health Lexington, Richmond and Corbin were among a select group of hospitals nationwide recognized by the U.S. Department of Health and Human Services f…
MassBiologics receives orphan drug status from FDA for hepatitis C treatment – Medical Xpress
MassBiologics receives orphan drug status from FDA for hepatitis C treatmentMedical XpressComplications from chronic HCV infection are the most common indications for liver transplantation today. For patients with end-stage liver disease or hepatocellu…
TGen, Barrow, Phoenix Children's Land $4M for Brain Injury RNA Sequencing … – GenomeWeb
|
TGen, Barrow, Phoenix Children’s Land $4M for Brain Injury RNA Sequencing …
GenomeWeb These complications can cause loss of blood flow in the brain, death of brain tissues, and hemorrhagic stroke, each of which can affect brain injury patients days after they have experienced their traumas. Currently, only about half of patients with … |
New Stem Cells Findings from Temple University Discussed – HispanicBusiness.com
|
New Stem Cells Findings from Temple University Discussed
HispanicBusiness.com MethodsWe treated 397 patients who had disease with an age-adjusted classification of high risk or high-intermediate risk with five cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP plus rituximab.” Our news … |
NIPT, Oncology to Drive NGS MDx Market Growth by 2015; Most Tests to … – GenomeWeb
NIPT, Oncology to Drive NGS MDx Market Growth by 2015; Most Tests to …GenomeWebIn addition, NGS-based diagnostic tests are bound to emerge in other areas, such as infectious disease, HLA typing, idiopathic diseases, preventive medicine, and other gen…